{"filings":[{"id":2079118,"accession_number":"0001787306-26-000049","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-08-05T20:14:24+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.","Raised FY2026 net product sales guidance to $525M-$540M from $480M-$495M.","FDA approved ZORYVE cream 0.3% for children aged 2+; sNDA accepted for ZORYVE cream 0.05% in infants (PDUFA Feb 23, 2027).","CCO L. Todd Edwards resigns effective Aug 21; Robert Lisicki appointed interim CCO (base $555K, equity grants).","Positive operating cash flow $12.6M; cash $238.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1692357,"accession_number":"0001628280-26-048469","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-07-16T20:25:02+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Christopher Peetz to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Peetz appointed as Class III director effective July 15, 2026; term expires at 2029 annual meeting.","Peetz is co-founder and CEO of Mirum Pharmaceuticals; brings biopharma leadership and M&A experience.","Received initial option for 21,486 shares; eligible for prorated annual equity (~$350K) and $50K cash retainer.","Board determined Peetz qualifies as independent under SEC and Nasdaq rules; no committee assignment yet.","Appointment expands board from nine to ten members; no family or material transaction relationships disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945399,"accession_number":"0001628280-26-041883","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-06-09T20:05:26+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Shareholders approve all proposals; board adopts updated director compensation program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.","Ernst & Young ratified as independent auditor for fiscal year 2026.","Non-binding advisory vote approved named executive officer compensation.","Revised director comp: $50k base retainer, $350k initial option, annual $350k award (65% options, 35% RSUs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95452,"accession_number":"0001787306-26-000039","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.","Net loss of $11.3M ($0.09 per share) vs $25.1M loss in Q1 2025; positive operating cash flow of $2.2M.","FY 2026 revenue guidance maintained at $480M–$495M; cash and equivalents $224.3M at quarter end.","Submitted sNDA for ZORYVE cream 0.05% in atopic dermatitis for infants 3–24 months; initiated Phase 1 for ARQ-234.","Completed dermatology sales force expansion; hired head of Primary Care Franchise to target pediatric providers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":105398000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108538,"accession_number":"0001787306-26-000017","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).","Q4 net income $17.4M ($0.14 diluted EPS) vs net loss of $10.8M in Q4 2024; positive operating cash flow of $26.2M.","Raised 2026 net product revenue guidance to $480-495M from $455-470M.","Positive Phase 2 data for ZORYVE cream 0.05% in infants (3-24 months) with atopic dermatitis; sNDA submission expected Q2 2026.","sNDA accepted for ZORYVE cream 0.3% in plaque psoriasis down to age 2; PDUFA June 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":376072000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124986,"accession_number":"0001787306-25-000147","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Amit Munshi to Board; founder Chaudhuri retires, retains consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bhaskar Chaudhuri retired from Board and Compensation Committee chair on Dec 3, 2025; no disagreement.","Chaudhuri entered consulting agreement through June 30, 2027 with hourly rate; options continue to vest.","Amit Munshi appointed Class II director and Compensation Committee chair effective Dec 4, 2025.","Munshi received initial option for 16,502 shares; eligible for prorated annual equity of ~$300,000 and cash retainers of $50,000 (Board) + $15,000 (chair).","Munshi previously served as CEO of Arena Pharmaceuticals (acquired by Pfizer for $6.7B) and Orna Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124985,"accession_number":"0001787306-25-000142","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.","Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.","FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.","Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.","Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":246569000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141678,"accession_number":"0001787306-25-000122","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.","Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.","ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.","PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.","IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":147350000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159576,"accession_number":"0001787306-25-000096","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcutis sets director cash retainers at $50k-$35k, annual equity value at $300k; all proposals at annual meeting pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).","Equity: initial option up to $300k value for new directors; annual award ~$300k split 65% option (up to $195k) and 35% RSU (up to $105k).","Plan amended effective June 11, 2025; board approved revisions to attract and retain qualified directors.","Shareholders reelected directors Chaudhuri, Lin, Welgus; ratified Ernst & Young as auditor; approved non-binding say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159575,"accession_number":"0001787306-25-000091","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.","Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.","Latha Vairavan appointed CFO effective May 6, 2025.","Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.","PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":65846000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159574,"accession_number":"0001787306-25-000058","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.","Vairavan's base salary increased to $450,000, target annual bonus 45% of salary (max 67.5%), pro-rated for 2025.","Vairavan granted option to purchase 60,000 shares and 20,000 restricted stock units with standard vesting.","Topper's retirement not due to any dispute; he will receive severance benefits per existing agreement subject to release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177948,"accession_number":"0001787306-25-000028","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.","Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.","Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.","Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.","ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":196542000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177947,"accession_number":"0001787306-25-000004","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.","Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.","Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.","Gross-to-net similar to prior quarter; robust unit growth across portfolio.","Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":196542000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194655,"accession_number":"0001787306-24-000151","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.","Net loss $41.5M ($0.33/sh) vs $44.8M ($0.73/sh) in Q3 '23; operating cash burn improved 23% QoQ to $34.7M.","Blended gross-to-net improved to low 50% range from high 50% last quarter; approaching steady state for foam.","Amended $200M SLR loan: lower rate, maturity extended to Aug '29; prepaid $100M on Oct 8, 2024.","sNDA for ZORYVE foam in scalp/body psoriasis accepted; PDUFA May 22, 2025. Health Canada approval for foam in SD received."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":125182000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210958,"accession_number":"0001787306-24-000122","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.","Net loss $52.3M ($0.42/share) vs $71.0M loss in Q2 2023; cash $363.1M.","Entered co-promotion with Kowa Pharmaceuticals for primary care and pediatric promotion of ZORYVE.","Submitted sNDA for ZORYVE foam for scalp/body psoriasis; FDA approved cream 0.15% for atopic dermatitis.","Amended $200M term loan: rate reduced 150bps, maturity extended to June 2029, $100M prepay/re-draw option."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":80427000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229424,"accession_number":"0001787306-24-000090","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcutis stockholders elect three directors, ratify EY, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I director nominees elected: Terrie Curran (77.2M for), Halley Gilbert (75.8M for), Keith R. Leonard Jr. (59.3M for).","Ratification of Ernst & Young as auditor for FY2024 passed with 95,949,963 votes for, 6,661 against.","Non-binding advisory vote on named executive officer compensation approved: 56,906,215 for, 26,716,602 against.","Meeting held June 14, 2024; record date April 22, 2024 with 115,524,989 shares outstanding and entitled to vote.","Broker non-votes of 12,428,038 on director election and say-on-pay proposals, none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229423,"accession_number":"0001787306-24-000078","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.","Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.","PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).","Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.","Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":49569000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229422,"accession_number":"0001787306-24-000046","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints David Topper as CFO, replacing interim CFO John Smither","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Topper named CFO effective April 10, 2024; John Smither steps down and resigns April 30.","Topper receives $515k base salary, 45% target bonus, and equity awards of 310k options, 110k RSUs, 60k PSUs.","Topper brings 40+ years experience; most recently CFO at Inmagene, ex-General Atlantic, J.P. Morgan, Morgan Stanley.","Smither served as interim CFO since August 2023; previously Arcutis' first CFO leading IPO.","Topper's severance agreement includes 12 months base plus bonus, COBRA, and full equity acceleration on qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247981,"accession_number":"0001628280-24-008496","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Arcutis raises ~$161.6M in public offering of 18.2M shares at $9.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~18.2M shares at $9.50 via underwritten public offering, raising ~$161.6M net.","Underwriters fully exercised 30-day option to purchase additional 2,368,421 shares on Feb 29, 2024.","Net proceeds intended to fund commercialization, development, and approval for atopic dermatitis, scalp psoriasis, and psoriasis expansion.","Offering conducted under existing Form S-3 shelf registration (File No. 333-276794)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247980,"accession_number":"0001628280-24-007586","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Arcutis licenses ZORYVE to Sato for Japan; $25M upfront, up to $65M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $25M; up to $10M in regulatory milestones and $30M in sales milestones.","Royalties of low double-digit to mid-teen double-digit percentage on net sales in Japan.","Sato exclusively develops and commercializes ZORYVE cream and foam for dermatological indications in Japan.","Arcutis retains approval and oversight rights over development and commercialization activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247979,"accession_number":"0001787306-24-000029","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.","Full-year 2023 total revenue $59.6M (incl. $30.4M Huadong upfront); net loss $262.1M ($3.78/share).","R&D expenses fell 39% to $110.6M; cash & securities $272.8M as of Dec 31, 2023.","FDA approved ZORYVE foam for seborrheic dermatitis Dec 2023; launched Jan 2024.","PDUFA target date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":59606000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247978,"accession_number":"0001628280-24-005061","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcutis completes stock option exchange; 98% of eligible options surrendered for 2.13M new RSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Options to purchase 5.06M shares surrendered (~98% of eligible); 2.13M new RSUs issued.","CEO Todd Franklin Watanabe surrendered 584,500 options, received 264,882 new RSUs.","Executive officers participated; non-employee directors excluded. Exchange ratios 2:1, 2.5:1, 3:1 based on exercise price.","New RSUs vest quarterly over 1-3 years starting Feb 1, 2024, subject to continued service.","Surrendered options had exercise prices significantly above recent trading price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247977,"accession_number":"0001628280-24-001150","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcutis announces voluntary option exchange program for underwater stock options","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eligible employees/consultants can exchange options with exercise price >=$10.00 for fewer RSUs.","Exchange ratios: 2:1 for $10-$19.99, 2.5:1 for $20-$27.49, 3:1 for $27.50+.","Offer open Jan 16 to Feb 12, 2024; RSUs vest over 1-3 years starting May 1, 2024.","Replacement RSU vesting schedule depends on original option grant date (2020 or earlier: 1yr; 2021-2022: 2yr; 2023+: 3yr).","Program aims to retain talent, align interests, and reduce overhang of underwater options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265427,"accession_number":"0001787306-23-000132","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Arcutis' ZORYVE foam for seborrheic dermatitis in ages 9+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ZORYVE (roflumilast) topical foam 0.3% approved by FDA for seborrheic dermatitis.","Indicated for individuals 9 years of age and older.","Prior FDA approval exists for ZORYVE cream 0.3% for plaque psoriasis (ages 6+).","Approval expands Arcutis' commercial product portfolio into a new dermatology indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265426,"accession_number":"0001787306-23-000122","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.","ZORYVE plaque psoriasis prescriptions over 110k from nearly 9k prescribers; FDA approved expanded indication to children ages 6+.","sNDA submitted for roflumilast cream 0.15% for atopic dermatitis ages 6+; potential approval Q3 2024.","Completed $100M public offering in Oct 2023; amended SLR debt facility removing market cap covenant, requires $31M additional capital by Apr 2024.","Appointed Todd Edwards CCO and John Smither interim CFO; Huadong collaboration upfront $30M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":46080000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265425,"accession_number":"0001628280-23-034917","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcutis Biotherapeutics prices public offering of 32.5M shares and pre-funded warrants for ~$93.5M net","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 32.5M common shares at $2.50 each plus pre-funded warrants for 7.5M shares at $2.4999 each.","Net proceeds expected ~$93.5M after discounts and expenses; closing expected October 24, 2023.","Underwriters granted 30-day option to purchase up to 6M additional common shares.","Pre-funded warrants have $0.0001 exercise price and include 9.99% beneficial ownership limitation (adjustable to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265424,"accession_number":"0001628280-23-034688","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arcutis pre-announces Q3 revenue of $38.1M; ZORYVE approved for pediatric psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2023 total revenue of $38.1M: $8.1M net product revenue (ZORYVE) and $30M other revenue from Huadong Medicine license.","Cash, equivalents, and marketable securities of $228.1M as of Sep 30, 2023.","FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis in children ages 6-11, including intertriginous areas.","Positive topline data from INTEGUMENT-PED and INTEGUMENT-OLE trials for atopic dermatitis in pediatric patients.","Company implemented headcount reductions to align with pipeline reprioritization and improve financial flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":46080000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282622,"accession_number":"0001787306-23-000109","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints L. Todd Edwards as Chief Commercial Officer; Ayisha Jeter promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edwards joins from Incyte with 25+ years in dermatology/immunology at UCB and AbbVie.","He will lead ZORYVE cream launch for plaque psoriasis and prepare for future indications.","Ayisha Jeter promoted to SVP Marketing and Market Access, reporting to Edwards.","Edwards receives $500,016 base salary, 45% target bonus, equity grants of 240K options, 60K RSUs, 60K PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282618,"accession_number":"0001787306-23-000090","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K/A","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arcutis appoints John Smither as interim CFO with $550K salary, option grant of 125K shares at $8.54","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $550,000 and target annual bonus of 45% of base salary.","Option to purchase 125,000 shares at $8.54 per share, vesting 2.0833% monthly.","Severance provides up to 12 months base salary and bonus, plus COBRA reimbursement, upon qualifying termination during change in control.","Equity awards accelerate 100% upon qualifying termination during change in control period; performance awards vest at greater of target or actual.","Employment effective August 31, 2023; Smither reports to CEO and serves as principal financial and accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282621,"accession_number":"0001787306-23-000081","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis CFO Scott Burrows resigns; former CFO John Smither named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Burrows resigns as CFO effective Aug 31, 2023 to pursue external opportunity; no disagreement with company.","John Smither, Arcutis' first CFO (2019-2021), appointed interim CFO effective Aug 31, 2023.","Smither has over 25 years pharma finance experience, including CFO roles at Kythera, Unity, Sienna, and interim CFO at Kite.","Smither will serve as principal financial and accounting officer; compensation terms to be disclosed later.","Company has commenced search for permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282620,"accession_number":"0001787306-23-000079","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Arcutis Biotherapeutics signs license deal with Huadong for ZORYVE in Asia, receiving $30M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Arcutis grants exclusive license to Huadong for ZORYVE cream and ARQ-154 foam in Greater China and Southeast Asia.","Huadong pays $30 million upfront, with potential $24 million in development/regulatory milestones and $40.25 million in sales milestones.","Arcutis receives low double-digit to high-teen double-digit royalties on net sales during the royalty term.","Huadong is responsible for development, regulatory approval, and commercialization at its own expense.","The agreement covers dermatological indications and includes termination provisions for breach, insolvency, or IP challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282619,"accession_number":"0001787306-23-000076","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.","Net loss $71.0M ($1.16 per share) vs $67.4M ($1.31) in Q2 2022.","Cash and marketable securities $269.6M as of June 30 vs $410.8M at Dec 31, 2022.","Commercial coverage expanded to >130M lives (all 3 largest PBMs) for ZORYVE.","FDA action date Dec 16, 2023 for roflumilast foam in seborrheic dermatitis; sNDA for atopic dermatitis expected late Q3/early Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":7971000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301887,"accession_number":"0001787306-23-000068","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcutis Biotherapeutics shareholders re-elect three Class II directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 54.5M votes for, 358K against.","Non-binding advisory vote on named executive officer compensation approved with 43.8M for, 7.3M against.","Meeting held May 31, 2023; record date April 3, 2023 with 61,360,936 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301886,"accession_number":"0001787306-23-000048","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Lock, SVP and CCO since Oct 2019, resigns effective June 2, 2023 to attend to personal matters.","Ayisha Jeter, VP of Market Access since June 2020, appointed interim CCO.","Company has commenced search for a permanent chief commercial officer.","Lock led commercialization of ZORYVE (roflumilast) cream 0.3% for plaque psoriasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301885,"accession_number":"0001787306-23-000042","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.","Net loss $80.1M ($1.31/share) vs $64.3M ($1.27) in Q1 2022; SG&A rose to $42.9M.","Cash, equivalents, and marketable securities $333.3M; operating cash burn $80.3M in Q1.","Health Canada approved ZORYVE for plaque psoriasis; launch expected in coming weeks.","FDA accepted NDA for roflumilast foam (seborrheic dermatitis); target action date Dec 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2781000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321631,"accession_number":"0001787306-23-000022","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.","Net loss of $72.0M ($1.18/share) in Q4 2022 vs $71.3M ($1.42/share) in Q4 2021.","Full-year 2022 net loss $311.5M ($5.66/share) vs $206.4M ($4.18/share) in 2021.","Cash, equivalents, and marketable securities $410.8M as of Dec 31, 2022.","Positive Phase 3 atopic dermatitis results; NDA submitted for roflumilast foam in seborrheic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":3686000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339727,"accession_number":"0001628280-22-032097","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcutis reports positive Phase 3 results for roflumilast cream 0.15% in atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INTEGUMENT-1: 32.0% of roflumilast patients achieved IGA success vs 15.2% vehicle (p<0.0001); INTEGUMENT-2: 28.9% vs 12.0% (p<0.0001).","Key secondary endpoints met: EASI-75 (43.2% vs 22% in INTEGUMENT-1) and WI-NRS itch reduction (33.6% vs 20.7% in INTEGUMENT-1) at week 4.","Roflumilast cream was well-tolerated with low TEAEs; discontinuation rates low (<2%) in both trials.","Total 1,337 subjects enrolled across both trials (654 in INTEGUMENT-1, 683 in INTEGUMENT-2); completed study rates ~93% and 90%.","Company posted updated corporate presentation with trial details; results support potential NDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339726,"accession_number":"0001787306-22-000070","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.","Net loss $107.7M ($1.89 per share) vs $57.0M ($1.14) YoY; Ducentis acquisition added $0.51 per share.","R&D expenses $69.7M (incl. $30M Ducentis upfront); SG&A $35.5M on launch costs.","Cash, equivalents, and marketable securities $478.2M; $162M from Aug 2022 public offering and $125M debt draw.","Positive topline Phase 3 data for roflumilast foam in scalp/body psoriasis; enrollment completed in atopic dermatitis trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":725000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357064,"accession_number":"0001787306-22-000061","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Arcutis acquires Ducentis for ~$30M upfront; DS-234 for atopic dermatitis","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration ~$30M (~$16M cash + ~$14M in stock); contingent milestones up to ~$400M.","DS-234 is a CD200R agonist (checkpoint agonism) targeting atopic dermatitis, a large underserved market.","Arcutis had ~$283M cash as of June 2022 plus $285M from Aug financings; deal not material to financial plans.","Closing expected Q3 2022; no stockholder approval required; Ducentis CSO retained as consultant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357063,"accession_number":"0001787306-22-000057","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Neha Krishnamohan to Board of Directors and audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10; Krishnamohan appointed Class III director and audit committee member.","Krishnamohan is CFO and EVP of Corporate Development at Kinnate Biopharma; previously VP at Goldman Sachs.","Received stock option for 29,482 shares vesting over three years; eligible for $40,000 annual retainer plus $10,000 for audit committee.","Krishnamohan worked on Arcutis' 2020 IPO while at Goldman Sachs.","Appointment effective September 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357062,"accession_number":"0001628280-22-021347","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcutis Biotherapeutics closes underwritten public offering of 8.625M shares at $20, net proceeds ~$161.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 7.5M shares plus full exercise of over-allotment of 1.125M shares at $20 per share.","Net proceeds approximately $161.7M after underwriting discounts and expenses.","Proceeds to fund development, approval, commercial launch for ZORYVE and general corporate purposes.","Underwriters include Morgan Stanley, Cowen, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357061,"accession_number":"0001787306-22-000050","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q2 net loss $67.4M; FDA approved ZORYVE for plaque psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved ZORYVE (roflumilast cream) for plaque psoriasis in patients 12+; launch expected in coming weeks.","Positive Phase 3 topline for roflumilast foam in seborrheic dermatitis; NDA submission planned Q1 2023.","Completed enrollment in INTEGUMENT-1 atopic dermatitis trial; topline data by end of 2022.","Cash $283.4M at June 30; pro forma ~$570M after $162M equity net + $125M debt draw.","Q2 net loss $67.4M ($1.31/sh) vs $42.0M ($0.84/sh) in Q2 2021, driven by R&D and G&A increases."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357060,"accession_number":"0001628280-22-020207","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.03","8.01","9.01"],"status":"ready","headline":"Arcutis gets FDA approval for ZORYVE (roflumilast) cream 0.3% for plaque psoriasis; draws $125M in debt","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.","First and only topical PDE4 inhibitor approved for plaque psoriasis; once-daily, steroid-free, no duration limit.","Commencing $125M drawdown of Tranche B term loans from SLR Investment Corp. to fund launch and pipeline.","Product expected to be available via wholesalers and dermatology pharmacies by mid-August 2022.","DERMIS-1/2 Phase 3 trials: 42% and 37% IGA success at Week 8 (P<0.0001); itch reduction as early as Week 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375611,"accession_number":"0001628280-22-016698","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcutis Biotherapeutics reports positive Phase 3 STRATUM results for roflumilast foam in seborrheic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)","50.7% achieved an IGA score of clear at week 8 compared to 28.2% with vehicle (p<0.0001)","Treatment was well-tolerated; discontinuation due to adverse events was 0.7% for roflumilast vs 2.0% for vehicle","NDA submission to FDA for roflumilast foam in seborrheic dermatitis anticipated in first half of 2023"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375610,"accession_number":"0001787306-22-000038","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcutis stockholders elect all three Class II directors and ratify Ernst & Young","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bhaskar Chaudhuri received 39.76M votes for, 3.83M withheld; Howard Welgus 30.92M for, 12.66M withheld; Sue-Jean Lin 39.09M for, 4.49M withheld.","Ratification of Ernst & Young as independent auditor for FY 2022: 47.07M for, 48k against, 14k abstain.","Non-binding advisory vote on executive compensation: 41.01M for, 2.07M against, 502k abstain.","Advisory vote on frequency of say-on-pay: majority (43.40M votes) favored one year.","About 51.4M shares outstanding and entitled to vote; broker non-votes were 3.55M on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375609,"accession_number":"0001787306-22-000030","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.","Cash & securities $344.8M at Mar 31, down from $388.6M at Dec 31 2021; ATM added $14.5M.","PDUFA action date July 29, 2022 for roflumilast cream in plaque psoriasis; commercial prep underway.","Completed enrollment of pivotal Phase 3 trials for roflumilast foam in seborrheic dermatitis and scalp/body psoriasis.","R&D spend $40.6M vs $21.6M; G&A $22.0M vs $14.5M, driven by clinical and launch preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393951,"accession_number":"0001787306-22-000008","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q4 2021 net loss of $71.3M, cash $388.6M; FDA accepted NDA for roflumilast cream","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.3M ($1.42 per share) for Q4 2021 vs $34.0M ($0.79) in Q4 2020.","Cash, equivalents and marketable securities $388.6M as of Dec 31, 2021; runway extended into 2024.","FDA accepted NDA for roflumilast cream in plaque psoriasis with PDUFA date July 29, 2022.","Completed enrollment of Phase 3 trial for roflumilast foam in seborrheic dermatitis; topline data mid-2022.","Secured $225M non-dilutive loan facility from SLR Capital Partners in December 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412501,"accession_number":"0001787306-21-000033","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Arcutis secures $225M non-dilutive debt facility; FDA accepts NDA for roflumilast cream (PDUFA July 2022)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$75M drawn at closing; additional $125M available upon FDA approval of roflumilast cream for plaque psoriasis; $25M upon revenue milestones.","Loan maturity January 2027; interest-only period for entire five years; floating rate = 7.45% + 1M SOFR.","FDA accepted NDA for roflumilast cream (psoriasis) with PDUFA target action date of July 29, 2022.","Proceeds extend cash runway into 2024; non-dilutive financing from SLR Capital Partners.","Loan secured by substantially all assets; prepayment premiums of 3%/2%/1% declining over time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412500,"accession_number":"0001787306-21-000029","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.","Submitted NDA to FDA for roflumilast cream for plaque psoriasis based on Phase 3 DERMIS trials.","Initiated pivotal Phase 3 trial of roflumilast foam in scalp/body psoriasis; topline expected H2 2022.","Terminated Phase 2a trial of ARQ-252 in vitiligo due to inadequate local drug delivery.","R&D expense $40.6M vs $32.7M YoY; G&A expense $16.5M vs $5.6M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412499,"accession_number":"0001787306-21-000021","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.","Indication covers adults and adolescents; submission date October 4, 2021.","Roflumilast cream is a topical PDE4 inhibitor, a novel mechanism for psoriasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-04T23:59:59+00:00|412499"}